SysteMHC v.231201
Home Datasets Download Help About Update

Showing details for project SYSMHC00019



SampleID NumReplicates Organism TissueType CellType MHCAllele
SampleID NumReplicates Organism TissueType CellType MHCAllele
SYSMHC00019_Wangq_161024_Costello_USA_LA3ST 4 Human DRB1_0301,DRB1_1501
SYSMHC00019_Wangq_161024_Costello_USA_LA4ST 4 Human DRB1_1101,DRB1_1302
SYSMHC00019_Wangq_161024_Costello_USA_LA5PB 5 Human DRB1_0301,DRB1_0305
SYSMHC00019_Wangq_161024_Costello_USA_LA5SF 5 Human DRB1_0301,DRB1_0305
SYSMHC00019_Wangq_161024_Costello_USA_LA5ST 4 Human DRB1_0301,DRB1_0305
SYSMHC00019_Wangq_161024_Costello_USA_LA6ST 2 Human DRB1_0103,DRB1_0301
SYSMHC00019_Wangq_161024_Costello_USA_LA7SF_QE 1 Human DRB1_0403,DRB1_1501
SYSMHC00019_Wangq_161024_Costello_USA_LA7ST 2 Human DRB1_0403,DRB1_1501
SYSMHC00019_Wangq_161024_Costello_USA_LA8SF_QE 2 Human DRB1_0401,DRB1_1001
SYSMHC00019_Wangq_161024_Costello_USA_LA8ST_QE 1 Human DRB1_0401,DRB1_1001
SYSMHC00019_Wangq_161024_Costello_USA_RA2SF 5 Human DRB1_0101,DRB1_0401
SYSMHC00019_Wangq_161024_Costello_USA_RA2ST_QE 1 Human DRB1_0101,DRB1_0401
SYSMHC00019_Wangq_161024_Costello_USA_RA3ST 4 Human DRB1_0101,DRB1_0401
SYSMHC00019_Wangq_161024_Costello_USA_RA4PB 3 Human DRB1_0401,DRB1_1501
SYSMHC00019_Wangq_161024_Costello_USA_RA4SF 3 Human DRB1_0401,DRB1_1501
SYSMHC00019_Wangq_161024_Costello_USA_RA5ST 4 Human DRB1_0801,DRB1_1501



Detailed view of sample SYSMHC00019_Wangq_161024_Costello_USA_LA5ST



ID SampleID RawFileName Organism Process Tissue Type Cell Type Culture Conditions Disease State Comments MHCClass MHCAllele PubMed ID Peptide Isolation Method Antibody Mass Spectrometer LC System iRT Peptides Acquisition Mode Fragmentation Method Gradient Gradient Length Flow Rate Replicate Number
ID SampleID RawFileName Organism Process Tissue_Type Cell_Type Culture_Conditions Disease_State Comments MHCClass MHCAllele PubMed_ID Peptide Isolation_Method Antibody Mass_Spectrometer LC_System iRT_Peptides Acquisition_Mode Fragmentation_Method Gradient Gradient_Length Flow_Rate Replicate_Number
SYSMHC00019 SYSMHC00019_Wangq_161024_Costello_USA_LA5ST SYSMHC00019_LA5ST_3_Orbitrap.RAW Human in vivo Synovium Lyme arthritis disease duration 4 years class II DRB1_0301,DRB1_0305 27726376 native Immunoaffinity L243 Orbitrap XL Waters noAcquity UPLC no DDA CID Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN. 52 min .5 uL/min 1
SYSMHC00019 SYSMHC00019_Wangq_161024_Costello_USA_LA5ST SYSMHC00019_LA5ST_1_Orbitrap.RAW Human in vivo Synovium Lyme arthritis disease duration 4 years class II DRB1_0301,DRB1_0305 27726376 native Immunoaffinity L243 Orbitrap XL Waters noAcquity UPLC no DDA CID Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN. 52 min .5 uL/min 2
SYSMHC00019 SYSMHC00019_Wangq_161024_Costello_USA_LA5ST SYSMHC00019_LA5ST_2_Orbitrap.RAW Human in vivo Synovium Lyme arthritis disease duration 4 years class II DRB1_0301,DRB1_0305 27726376 native Immunoaffinity L243 Orbitrap XL Waters noAcquity UPLC no DDA CID Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN. 52 min .5 uL/min 3
SYSMHC00019 SYSMHC00019_Wangq_161024_Costello_USA_LA5ST SYSMHC00019_LA5ST_4_Orbitrap.RAW Human in vivo Synovium Lyme arthritis disease duration 4 years class II DRB1_0301,DRB1_0305 27726376 native Immunoaffinity L243 Orbitrap XL Waters noAcquity UPLC no DDA CID Buffer A contained 1% acetonitrile (ACN) and 0.1% formic acid in water, and buffer B contained 1% water and 0.1% formic acid in ACN. 52 min .5 uL/min 4